Epizyme Inc
F:EPE
Operating Margin
Epizyme Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
327.7B USD |
30%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
151.7B USD |
25%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
137.6B USD |
38%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.2B USD |
38%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
120.1B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
64.7B USD |
29%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
37.9B USD |
-5%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
30.9B EUR |
8%
|
Epizyme Inc
Glance View
Nestled in the bustling world of biotechnology, Epizyme Inc. emerged as a dynamic player within the realm of epigenetic medicine. The company carved a niche for itself by focusing on the development and commercialization of novel therapeutics that target the epigenetic regulation of gene expression. Founded with a vision to harness the power of small molecules to modulate the proteins responsible for reading and interpreting the epigenetic code, Epizyme strives to innovate therapies that can treat patients with serious unmet medical conditions, particularly in oncology. Its flagship product, Tazemetostat, received FDA approval for the treatment of certain types of lymphoma and soft tissue sarcoma. This marked a significant milestone for the company, confirming its ability to transform complex biological science into tangible, market-ready solutions. With a strategic approach centered on precision medicine, Epizyme monetizes its innovations primarily through direct sales, partnerships, and licensing agreements. The company’s revenue streams are buoyed by its collaborations with other biotechnology and pharmaceutical companies keen on leveraging Epizyme’s specialized expertise to advance their own drug development programs. Moreover, by advancing a robust pipeline of epigenetic therapies that span a variety of therapeutic areas, Epizyme positions itself to capture a growing share of the biotechnology market. Intellectual property and sophisticated R&D capabilities underpin its business model, enabling the company not only to produce groundbreaking therapies but also to secure significant market opportunities in an increasingly competitive landscape.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Epizyme Inc's most recent financial statements, the company has Operating Margin of -370.1%.
You don't have any saved screeners yet